The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions

The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of Toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to over...

Descripción completa

Detalles Bibliográficos
Autores principales: Koido, Shigeo, Homma, Sadamu, Okamoto, Masato, Namiki, Yoshihisa, Takakura, Kazuki, Uchiyama, Kan, Kajihara, Mikio, Ohkusa, Toshifumi, Gong, Jianlin, Tajiri, Hisao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782132/
https://www.ncbi.nlm.nih.gov/pubmed/24073361
http://dx.doi.org/10.4161/onci.24660
Descripción
Sumario:The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of Toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to overcome the immunosuppressive effects of transforming growth factor β1.

Ejemplares similares